[In vitro activity of human recombinant interferon gamma against SARS-CoV-2 virus].

INTRODUCTION: The development of drugs against SARS-CoV-2 continues to be crucial for reducing the spread of infection and associated mortality. The aim of the work is to study the neutralization of the SARS-CoV-2 virus with interferon gamma preparations in vitro. MATERIALS AND METHODS: The activity of recombinant human interferon gamma for intramuscular and subcutaneous administration of 500,000 IU and for intranasal administration of 100,000 IU against the SARS-CoV-2 virus in vitro was studied. The methodological approach of this study is based on the phenomenon of a decrease in the number of plaques formed under the action of a potential antiviral drug. RESULTS: The antiviral activity of recombinant interferon gamma has been experimentally confirmed, both in preventive and therapeutic application schemes. The smallest number of plaques was observed with the preventive scheme of application of the tested object at concentrations of 1000 and 333 IU/ml. The semi-maximal effective concentration (EC50) with the prophylactic regimen was 24 IU/ml. DISCUSSION: The preventive scheme of application of the tested object turned out to be more effective than therapeutic one, which is probably explained by the launch of the expression of various interferon-stimulated genes that affect to a greater extent the steps of virus entry into the cell and its reproduction. CONCLUSION: Further study of the effect of drugs based on recombinant interferon gamma on the reproduction of the SARS-CoV-2 virus for clinical use for prevention and treatment is highly relevant.

Study of the medicine mestamidin®-nos virucidal activity of against influenza and ard pathogens

Introduction. Respiratory diseases have always been a serious threat to public health, but in 2020 the situation deteriorated significantly due to the rapid development of the coronavirus infection COVID-19. Due to the lack of available means of ethiotropic therapy and the still insufficient coverage of the general population with vaccination, disinfectants, as well as topical preparations that prevent the penetration of the virus into the body, play an important role in preventing the spread of infection. Aim of the study. This work is devoted to the study of the virucidal activity of the medicine Mestamidin-nos against respiratory viruses, namely influenza A and B viruses, parainfluenza, respiratory syncytial, adenovirus and seasonal coronavirus. Materials and methods. This study was carried out by the suspension method according to MU 3.5.2431-08 “Study and assessment of the virucidal activity of disinfectants”. Results. It was shown that for all studied viruses the use of the compound for 60 minutes led to a complete (up to 0 lgTID50) or sufficient (4 lgTID50) decrease in the viral titer. In the case of a study of a compound with a protein load (imitating strong organic pollution), the effectiveness of the compound was significantly reduced against influenza A viruses, one of the strains of influenza B virus, adenovirus and seasonal coronavirus. Conclusion. Based on the results of the study, it can be concluded that the effective inhibition of pathogens of influenza and acute respiratory infections using the compound MesaMidin®-nos in the absence of strong organic pollution. © Shtro A.A., Galochkina A.V., Nikolaeva Y.V., Petukhova G.D., Fedorova V.A., Lioznov D.A. 2021.